Stockscreener 앱 받기
2.68
1.13%
0.03
시간 외 거래:
2.70
0.02
+0.75%
전일 마감가:
$2.65
열려 있는:
$2.65
하루 거래량:
917.63K
Relative Volume:
0.74
시가총액:
$290.37M
수익:
$27.08M
순이익/손실:
$-37.00M
주가수익비율:
-5.1538
EPS:
-0.52
순현금흐름:
$-18.46M
1주 성능:
-10.96%
1개월 성능:
-8.22%
6개월 성능:
+83.56%
1년 성능:
+7.20%
1일 변동 폭
$2.60
$2.748
1주일 범위
$2.49
$3.04
52주 변동 폭
$1.05
$3.475
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.68 | 287.11M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Why Aclaris Therapeutics Inc. stock could rally in 2025Long-Term Growth Stocks & Superior Growth Trading - ulpravda.ru
Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target - Investing.com Canada
Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans - MarketBeat
Aclaris Therapeutics Reports Positive Phase 1a Data For ATI-052 - Nasdaq
Aclaris advances ATI-052 after positive Phase 1a results - TipRanks
Aclaris Therapeutics Announces Positive Interim Results from Phase 1a Trial of ATI-052 - TradingView — Track All Markets
Aclaris reports positive results for anti-inflammatory drug ATI-052 By Investing.com - Investing.com Australia
ACRS: ATI-052 showed best-in-class potential in phase 1a, enabling rapid advancement to phase 1b trials - TradingView — Track All Markets
Aclaris Therapeutics Reports Positive Interim Results for ATI-052 Phase 1a Trials and Outlines Future Development Plans - Quiver Quantitative
New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care - Stock Titan
What analysts say about Aclaris Therapeutics Inc 8AT stockStock Market Trends & Affordable Portfolio Trading - earlytimes.in
Hair Loss Treatment Market Booming with Rapid Growth Through 2032 | Viviscal, Cipla Inc., Aclaris Therapeutics, Inc. - openPR.com
Three Bridge Wealth Advisors LLC Takes Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Why Aclaris Therapeutics Inc. stock remains undervaluedMoving Average Strategies & Exceptional Profit Trading - bollywoodhelpline.com
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
What drives Aclaris Therapeutics Inc stock priceEarnings Forecast Updates & Big Profit Low Trading - earlytimes.in
Aclaris joins Nasdaq biotech index, marking milestone for clinical-stage firm - MSN
Aclaris Joins Nasdaq Biotech Index, Marking Milestone for Clinical-Stage Firm - MyChesCo
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to NASDAQ Biotechnology Index - marketscreener.com
Gains Report: Is Aclaris Therapeutics Inc stock a good choice for value investorsJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - moha.gov.vn
Dow Update: What valuation multiples suggest for Aclaris Therapeutics Inc. stockWeekly Trade Review & Accurate Buy Signal Notifications - Улправда
Is Aclaris Therapeutics Inc. (8AT) stock good for wealth creationWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - Улправда
Will Aclaris Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Breakouts & Risk Managed Investment Strategies - Улправда
Why Aclaris Therapeutics Inc. stock could see breakout soonJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда
Why Aclaris Therapeutics Inc. stock is rated strong buyJuly 2025 Gainers & Free Community Consensus Stock Picks - Улправда
How analysts rate Aclaris Therapeutics Inc. stock todayJuly 2025 Catalysts & Safe Capital Preservation Plans - Улправда
Layoff Watch: Why Aclaris Therapeutics Inc. stock could rally in 2025 - Улправда
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index - Investing News Network
Aclaris Therapeutics Included in Nasdaq Biotechnology Index - marketscreener.com
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025 - Quiver Quantitative
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - The Manila Times
Is Aclaris Therapeutics Inc. stock safe for conservative investorsJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 25% Share Price Surge Not Quite Adding Up - simplywall.st
Rally Mode: Is Aclaris Therapeutics Inc. (8AT) stock good for wealth creationTrade Risk Assessment & AI Forecasted Entry/Exit Points - Улправда
Aclaris Therapeutics Earnings Notes - Trefis
Can Upcoming ATI-2138 And Bosakitug Data Drive Momentum For Aclaris Therapeutics In 2026? - RTTNews
Aclaris Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
It is Poised to be a Bull Market for Aclaris Therapeutics Inc (ACRS) - setenews.com
Can Aclaris Therapeutics Inc. stock deliver sustainable ROE2025 Key Highlights & Consistent Return Investment Signals - Newser
Why Aclaris Therapeutics Inc. (8AT) stock is a must watch tickerTrade Risk Assessment & Weekly Stock Performance Updates - Newser
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
How Aclaris Therapeutics Inc. (8AT) stock correlates with oil markets2025 Growth vs Value & Technical Pattern Recognition Alerts - Newser
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):